Niagen Bioscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.7%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$141.4Mnext fiscal year
FY EPS (est.)
$0.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Tru Niagen Net Sales Quarterly22.4M
Niagen Ingredient Net Sales Quarterly8.2M
Total Net Sales Quarterly31.5MTarget: 10% to 15% growth for FY 2026
Gross Profit Margin Quarterly63.5%Target: Slight full-year improvement compared to 2025
Watch Items
- A.S. Watson Order VariabilityTrigger: Significant drop in B2B distribution salesAction: Optimize alternative international distributor partnerships and accelerate direct-to-consumer e-commerce channels.
- Niagen Plus Telehealth and Clinical ExpansionTrigger: Adoption rate of at-home injection kits and cruise ship clinic partnershipsAction: Monitor clinician-directed telehealth platform metrics and expand 503B compounding partner network.
Research as of 19 Jun 2026